metabolic research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-12. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
==== Cyprus ==== The New York Times published an exposé revealing an extensive three-year phishing campaign aimed against diplomats based in Cyprus. After accessing the state system the hackers had access to the European Union's entire exchange database. By login into Coreu, hackers accessed communications linking all EU states, on both sensitive and not so sensitive matters. The event exposed poor protection of routine exchanges among European Union officials and a coordinated effort from a foreign entity to spy on another country. "After over a decade of experience countering Chinese cyberoperations and extensive technical analysis, there is no doubt this campaign is connected to the Chinese government", said Blake Darche, one of the Area 1 Security experts – the company revealing the stolen documents. The Chinese Embassy in the US did not return calls for comment. In 2019, another coordinated effort took place that allowed hackers to gain access to government (gov.cy) emails. Cisco's Talos Security Department revealed that "Sea Turtle" hackers carried out a broad piracy campaign in the DNS countries, hitting 40 different organizations, including Cyprus.
== Further reading == Thakkar, Santosh V.; Allegre, Kevin M.; Joshi, Sangeeta B.; Volkin, David B.; Middaugh, C. Russell (2012). "An application of ultraviolet spectroscopy to study interactions in proteins solutions at high concentrations". Journal of Pharmaceutical Sciences. 101 (9): 3051–3061. Bibcode:2012JPhmS.101.3051T. doi:10.1002/jps.23188. ISSN 0022-3549. PMID 22581726. Scott Huffman, Keyur Soni and Joe Ferraiolo UV-Vis Based Determination of Protein Concentration: Validating and Implementing Slope Measurements Using Variable Pathlength Technology by September 2014 http://www.bioprocessintl.com/manufacturing/antibody-non-antibody/uv-vis-based-determination-protein-concentration-validating-implementing-slope-measurements-using-variable-pathlength-technology/
== Function == The edited region contains a proposed heparin binding site and is also part of the recognition sequence for proteolytic cleavage. Heparin binding inhibits cell binding and cell adhesion functions of the protein. Cleavage which occurs at amino acid position 97 reduces heparin binding but modulates the growth stimulatory activity of the protein. Since the editing site occurs within this proposed heparin binding region the effects of editing may have implications for heparin binding and proteolytic cleavage and therefore have other affects downstream. Since the protein has been implicated in these processes it is believed editing might effect apoptosis, regulation of cell growth and angiogenesis.
Sources: en.wikipedia.org
The radio source PSR J1928+15 (observed in 2005 near the Galactic disk, at a frequency of 1.44 GHz, at Arecibo) could be of extraterrestrial origin. James and Dominic Benford consider three scenarios in which the cost factor is taken into account. If the source is cost-optimized, it belongs to a civilization of Type 0.35 (the Earth being of Type 0.73). If it is not cost-optimized and operates with a small antenna, the Type is 0.86. With a large antenna, it would be from a Type 0.66. Using this cost/efficiency method, it can be estimated that low-intensity sources may be the most prevalent, but also the most difficult to observe.
During Mahathir's first tenure from 1981 to 2003, Malaysia experienced significant economic growth and modernisation, with his government promoting industry-wide privatisation and initiating major infrastructure projects, such as the North–South Expressway and the Kuala Lumpur City Centre. His policies were credited with transforming Malaysia into one of Southeast Asia's most dynamic emerging economies. He was a dominant political figure, securing five consecutive general election victories and maintaining leadership of the UMNO despite internal challenges. Mahathir continued pro-bumiputera policies and oversaw Malaysia's relatively swift recovery from the 1997 Asian financial crisis, aided by capital controls and stimulus measures that diverged from IMF prescriptions. As prime minister, he was a strong proponent of Asian values and alternative development models, and he played a prominent role in the Muslim world. In 1987, he ordered the detention of numerous activists under Operation Lalang, and his administration was involved in the 1988 Malaysian constitutional crisis, which raised concerns about judicial independence. He supported a constitutional amendment that stripped the royalty of criminal immunity, a move widely regarded as a legal reform strengthening the rule of law. In 1998, the dismissal of deputy Anwar Ibrahim sparked the Reformasi and became a major point of political debate in Malaysia.
Alcohol: 6-12 h Marijuana: 1-24h A disadvantage of saliva based drug testing is that it is not approved by FDA or SAMHSA for use with DOT / Federal Mandated Drug Testing. Oral fluid is not considered a bio-hazard unless there is visible blood; however, it should be treated with care.
=== 2016–present: Departure from Valve === Laidlaw announced his departure from Valve in January 2016. He said the primary reason for his departure was his age, and that he planned to return to writing stories. He felt he was becoming a "negative force" at Valve and hampering the creative process, saying: "I think at some point you need to let the people who are the fans and the creators who've come in because of what they learned from you maybe, and let them have that. We didn't need me going, 'Well, the G-Man wouldn't do that in my day.'" Laidlaw also tired of the FPS genre and of solving storytelling problems in a Half-Life-style narrative. He said he had "always hoped that we'd stumble into a more expansive vocabulary or grammar for storytelling within the FPS medium, one that would let you do more than shoot or push buttons, or push crates". On August 25, 2017, Laidlaw published a short story, "Epistle 3", describing it as "a snapshot of a dream I had many years ago". Journalists interpreted it as a summary of what could have been the plot for Half-Life 2: Episode Three. Laidlaw denied this, saying "all the real story development can only happen in the crucible of developing the game". In 2023, Laidlaw said he regretted publishing the story. He said he had been "deranged" and "completely out of touch" at the time, and that it had created problems for his former colleagues at Valve. In 2020, Valve released the VR game Half-Life: Alyx.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.